FDA published a major revision to Import Alert 66-80 on September 21, 2026. The alert directs field personnel to consider detention without physical examination for certain foreign-sourced GLP-1 receptor agonist active pharmaceutical ingredients, except products and manufacturers identified on the alert's Green List.
The revision matters because it shows how far a serious supply-chain review extends beyond a polished certificate. FDA says it evaluated 48 GLP-1 API sites and found 21% noncompliant under the cited federal requirements, either because records indicated manufacturing-practice problems or because a firm failed to respond to a records request on time.
What detention without physical examination means
DWPE is an import-control mechanism. Under this alert, an eligible shipment can be detained at the border without FDA first physically examining that specific shipment. The stated basis is the appearance that the imported API may be adulterated because manufacturing methods, facilities, or controls do not appear to conform to current good manufacturing practice requirements.
The Green List is the exception described in the alert. It identifies specified products from registered foreign manufacturers whose facilities and associated products appear, based on FDA's evaluation of recent evidence, to be in compliance with the applicable manufacturing requirements.
That status should be read narrowly. It does not transform a downstream vial, compounded preparation, or research product into an FDA-approved finished drug. It addresses the import treatment of specified API sources under this particular alert.
Why one COA is not enough
FDA includes recent lot certificates among the records a manufacturer may submit when asking to be added to the Green List. But the certificate is one item in a much larger evidence package.
- Release specifications and test methodsFDA asks for scientific justification covering attributes such as impurities, potency, and microbial quality for APIs intended for injectable products.
- Method validation or verificationA result is more useful when the method is demonstrated to perform as intended—not merely named in a certificate footer.
- Stability evidenceThe alert requests stability protocols, acceptance criteria, testing intervals, and summaries rather than assuming that a release result remains unchanged indefinitely.
- Manufacturing and batch recordsFDA lists process validation, a master batch record, a recent manufacturing record, equipment information, and quality-unit responsibilities.
- Exceptions and complaint historyOut-of-specification investigations, complaints, adverse events, recalls, and returns help show how failures are identified and handled.
What changed in the September revision
The revision updates the Green List guidance, adds product codes, and adds orforglipron API from three manufacturers and an orforglipron solid-dispersion intermediate from one manufacturer. The alert's product descriptions also cover named GLP-1 APIs and broader categories that may include semaglutide, tirzepatide, liraglutide, retatrutide, and related substances.
Those entries describe products within an import-control framework. They should not be converted into a claim that every listed ingredient, manufacturer, or finished product is approved, safe, effective, or suitable for a particular use.
How this changes a public COA review
Compound IQ's seven-category framework still starts with the lot document: identity, purity, measured content, lot traceability, sterility, endotoxin, and contaminants. The import alert adds a second layer of questions that a single public COA usually cannot answer.
- 01Match the exact lot
Confirm that the product, lot, client, laboratory, dates, and verification record align.
- 02Read the methods and specifications
A percentage without the analytical method, acceptance criteria, and measured-content context is incomplete.
- 03Separate API from finished-product evidence
An API manufacturer's status does not independently verify the composition, handling, or labeling of every downstream vial.
- 04Look for missing quality-system evidence
Stability, process validation, out-of-specification investigations, and complaint history rarely fit on a consumer-facing COA.
- 05Keep regulatory and analytical claims separate
A strong assay is not regulatory approval, while an import action is not a laboratory result for every individual lot.
The Compound IQ takeaway
The FDA revision does not make COAs irrelevant. It shows why they must be read as one layer of evidence.
A credible public record should still identify the exact lot and report methods and results clearly. But readers should not stretch a single certificate into proof of a complete manufacturing system, an approved supply chain, or suitability for use. Evidence before the claim means keeping those boundaries visible.
This article analyzes public FDA records. It is research education, not medical or legal advice, and it does not assess any product for human use. No affiliate links appear in this article.